SCOLARI, MJ. Rediscovering old acquaintances: the possible role of hydroxychloroquine, chloroquine, ivermectin, and teicoplanin in the treatment of COVID-19. []. , 30, 2, pp.127-130.   15--2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2020000200012.

The coronavirus (COVID-19) pandemic triggered in China in December 2019 represents a global therapeutic challenge. To date, a wide variety of drugs, with potential to treat the disease, have been proposed. The vast majority of them, are medications that existed, prior to the pandemic, used to treat other pathologies. However, none has demonstrated to be effective in well designed clinical trials that specifically endorse its use for COVID-19. In this context, their cost and availability becomes a fundamental factor, particularly in Latin America. This article will review key characteristics of known and affordable medications in Argentina and the rest of Latin America: hydroxychloroquine, chloroquine, ivermectin and teicoplanin.

: Coronavirus; hydroxychloroquine; chloroquine; ivermectin; teicoplanin.

        · |     · |     · ( pdf )